Ocular MG an Independent Predictor of MG Responsive to Corticosteroids
More than half of the young patients with myasthenia gravis (MG) responded well to the use of corticosteroids.
Read More
New Regulations on PBMs Become Law: What This Means for Pharmacies Nationwide—A Q&A With Jesse Dresser, Esq
The Consolidated Appropriations Act of 2026 features new language that could change the way that pharmacy benefit managers (PBMs) operate in the US.
ACOs Improve Primary, Preventive Care Delivery for Medicare Beneficiaries
Beneficiaries in ACOs receive significantly higher rates of primary and preventive services, signaling value-based care’s impact on quality and chronic disease management.
PBM Reforms Signed Into Law, Reshaping Medicare Part D Drug Pricing Transparency
A spending bill advancing PBM reforms aims to delink Medicare Part D compensation from drug rebates and improve pricing transparency.
Telomere Length and Polygenic Risk Shape Endotypes in Idiopathic Pulmonary Fibrosis
Telomere length and polygenic risk independently influence IPF susceptibility, even among patients without rare genetic variants.
From Biologics to Bio-Machines: Top Takeaways From Maui Derm 2026
Maui Derm 2026 showcased groundbreaking advancements in dermatology, focusing on biologics, innovative treatments, and future technologies for skin health.
Is Rare Disease Policy a Stress Test of US Health Care?
The Orphan Drug Act revolutionized rare disease treatment, yet rising costs and access issues challenge equitable health care solutions.
Coalition's Conversation: The Employer Perspective
Obesity market overview for employers: data on GLP-1s for obesity, digital solutions, and benefit strategies to control costs and outcomes.
FDA Flags Administration Concerns for Aquestive's Noninvasive Epinephrine Film
Aquestive Therapeutics receives a complete response letter for dibutepinephrine (Anaphylm), a sublingual epinephrine therapy.
FAQs About Glaucoma as Awareness Month Concludes
Glaucoma is a leading cause of blindness in the US, making awareness of the condition vital to obtaining the best outcomes.
Prior Authorization Ranked Top Barrier to Health Care Access After Cost
Prior authorization remains a major health care barrier, causing delays and frustrations for insured adults seeking necessary treatments.
Contributor: From Outreach to Outcomes—4 Steps to Stronger Medication Adherence
Addressing poor medication adherence should be a top priority in health plans to ensure short- and long-term benefits in health outcomes and financial stability.
Contributor: The Majority (57.5%) of Commercially Insured Patients Had 1 or More Chronic Conditions in 2024
Patients on commercial insurance were more likely to have at least 1 chronic condition, which can affect health care spending overall.
Strong Patient–Doctor Communication Improves Glaucoma Care: Ariana Levin, MD
Communicating to patients that they need to come to their annual checkup is important for eye doctors to convey to help treat their patients, says Ariana Levin, MD.
Watch
Mental Health Distress in Nonmelanoma Skin Cancer Largely Driven by Sociodemographic, Comorbid Factors
These findings suggest the mental health burden in nonmelanoma skin cancer reflects broader social and clinical factors rather than disease-specific effects.
Tildrakizumab Shows Long-Term Psoriasis Control for Hard-to-Treat Areas
Tildrakizumab at 100-mg and 200-mg doses showed long-term effectiveness for managing psoriasis in challenging areas in a real-world study.
Vutrisiran Improves Survival, Cardiovascular Outcomes Across Age Groups in ATTR-CM
Vutrisiran significantly reduces mortality and cardiovascular events in older patients with ATTR-CM, enhancing quality of life and functional capacity.
Health Equity & Access Weekly Roundup: January 30, 2026
Explore critical health equity issues as barriers to care access and health disparities that impact treatment for allergic rhinitis and childhood vaccinations.
Virtual Reality Intervention Increased Empathy for Patients With MG
Empathy, knowledge, and attitudes in care for patients with myasthenia gravis were improved when using a patient-centric immersive virtual reality intervention.
Photobiomodulation, Bio-Machines, and the Future of Dermatology
Discover how innovations in biology and engineering are transforming dermatology, featuring breakthroughs in laser therapies and precision medicine.
MASH Drug Efficacy Varied Widely Across Fibrosis, Resolution Outcomes
New research highlights the effectiveness of targeted therapies for metabolic dysfunction–associated steatohepatitis (MASH), guiding treatment decisions and trial designs.
Vision Rehabilitation Can Help Patients Unable to Prevent Vision Loss in Glaucoma: Jullia Rosdahl, MD, PhD
Although there are no means of preventing glaucoma, there are means of preventing long-term vision loss.
Glaucoma Awareness Month Shines Light on Eye Condition Known as the Silent Thief
Experts discuss the signs and symptoms, treatment methods, and the future of glaucoma as Glaucoma Awareness Month concludes.
AJMC® in the Press, January 30, 2026
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
AI-Supported Mammography Caught More Cancers During Screening
Standard double reading did not perform as well as artificial intelligence for looking at catching cancer and reduced the rate of breast cancer diagnosis by 12%.
Combination Therapy, Biologics, and Surgery Redefine HS Care in 2026
Vivian Shi, MD, discusses the evolving strategies for managing hidradenitis suppurativa, including biologics and combination therapies, at Maui Derm 2026.
Efficacy, Insurance Coverage Drive Alopecia Areata Treatment Preferences
New research suggests people with alopecia areata view hair regrowth efficacy as the most important factor when choosing a therapy, regardless of their disease severity.
Treatment for Glaucoma Continues to Evolve, Allowing Eye Doctors to Personalize Treatment: Manjool Shah, MD
The future of treating glaucoma relies on ophthalmologists and optometrists personalizing therapy to their patient, says Manjool Shah, MD.
Disparities in Allo-HCT Use for AML Persist Despite Advances
Disparities in access to allo-HCT for AML persist, highlighting the need for targeted interventions to ensure equitable treatment for all patients.
CLL Breakthrough: 100% Efficacy Reported for VenR Retreatment
This new study reveals venetoclax and rituximab effectively treat chronic lymphocytic leukemia, showing high response rates and prolonged progression-free survival.
